Association Between Serum Levels of Sestrin-2 and Galectin-3 and Atrial Remodelling in Patients with Atrial Fibrillation.

Objective: To explore the prognostic significance of Sestrin-2 and Galectin-3 levels in atrial fibrillation complicated by left atrial remodelling, aiming to offer novel insights for prevention, treatment, and follow-up strategies.

Study design: Analytical study. Place and Duration of the Study: Department of Cardiology, Second People's Hospital of Anhui Province, Hefei, China, from January 2021 to December 2023.

Methodology: A total of 188 patients with atrial fibrillation were enrolled and divided into two groups based on the presence or absence of atrial remodelling. Serum levels of Sestrin-2 and Galectin-3, along with baseline clinical data, laboratory examinations, and Doppler echocardiography results, were compared between the groups.

Results: The atrial remodelling group showed significantly higher levels of age, AST, Sestrin-2, Galectin-3, and left atrial diameter compared to the non-atrial remodelling group (p <0.05). Multivariate logistic regression analysis indicated that both Sestrin-2 and Galectin-3 were independent risk factors associated with atrial remodelling in patients with atrial fibrillation (p <0.05). The combined assessment of Sestrin-2 and Galectin-3 yielded an area under the receiver operating characteristic (ROC) curve of 0.854, facilitating precise identification of the incidence of atrial fibrillation.

Conclusion: The study found that serum levels of Sestrin-2 and Galectin-3 were significantly elevated in the atrial remodelling group compared to the non-atrial remodelling group, suggesting their potential clinical utility in predicting atrial remodelling in patients with atrial fibrillation. These findings are significant for the prevention and treatment of this condition.

Key words: Atrial fibrillation, Sestrin-2, Galectin-3, Atrial remodelling.